Objective: To investigate the suppression effect of exogenous fragile histidine triad (FHIT) gene on biological property of MEC-1 cells.
Methods: In order to study the FHIT function in MEC-1 cells, wild-type FHIT gene was transferred into mucoepidermoid carcinoma MEC-1 cells. The proliferation and kinetics, cell cycle, clonal forming rate, and apoptosis of MEC-1 cells, before and after FHIT gene transfection in vitro, and tumor loci formed on mice after injection of transferred MEC-1 cells in vivo were observed by immunochemical staining, flow cytometry analysis, and so on.
Results: It can be seen that exogenous FHIT gene transfer could significantly inhibit the proliferation and reduce the kinetics of MEC-1 cells in vitro, prolong DT from (21.03+/-0.41) h to (26.86+/-0.71) h, and also keep less cells in cell cycle phase S, whilst more cells in phase G1, Additionally, the exogenous FHIT was found to be able to remarkably suppress MEC-1 cells of forming tumor loci in nude mice by lessen tumor weight, and promote higher differentiation of MEC-1 cells to be mucous cells.
Conclusion: Exogenous FHIT gene could suppress the proliferation, tumorigenicity and improve the differentiation of MEC-1 cells, in vitro and in vivo.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Deficiency of miR-155 in leukemic B-cells results in cell cycle arrest and deregulation of MIR155HG/TP53INP1/CDKN1A/CCND1 network.
Arch Med Res
November 2024
Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address:
Background: Cell cycle progression and leukemia development are tightly regulated processes in which even a small imbalance in the expression of cell cycle regulatory molecules and microRNAs (miRNAs) can lead to an increased risk of cancer/leukemia development. Here, we focus on the study of a ubiquitous, multifunctional, and oncogenic miRNA-hsa-miR-155-5p (miR-155, MIR155HG), which is overexpressed in malignancies including chronic lymphocytic leukemia (CLL). Nonetheless, the precise mechanism of how miR-155 regulates the cell cycle in leukemic cells remains the subject of extensive research.
View Article and Find Full Text PDFS-(+)-mecamylamine increases the firing rate of serotonin neurons and diminishes depressive-like behaviors in an animal model of stress.
Neuroscience
December 2024
Departamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), PO Box 70250, Ciudad de México 04510, Mexico. Electronic address:
Mecamylamine, a noncompetitive blocker of nicotinic acetylcholine receptors (nAChRs), is the racemic mixture of two stereoisomers: S-(+)-mecamylamine (S-mec) and R-(-)-mecamylamine (R-mec), with distinct interactions with α4β2 nAChRs. It has been shown that mecamylamine increases glutamate release and excites serotonergic (5-HT) neurons in the dorsal raphe nucleus (DRN). In this study, we separately evaluated the effects of S-mec and R-mec on 5-HT neuron excitability.
View Article and Find Full Text PDFEngineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis.
Cancer Res Commun
September 2024
Department of Systems Biology, Beckman Research Institute, City of Hope National Comprehensive Cancer Center, Monrovia, California.
Article Synopsis
- SF3B1 is a critical RNA splicing gene frequently mutated in cancer, but studying its pathogenic effects has been challenging due to the lack of suitable cell line models.
- By comparing various genome editing techniques, the study found that prime editing, specifically using PE5max, was the most effective method for introducing the SF3B1 K700E mutation in multiple cell lines.
- The researchers introduced this mutation into chronic lymphocytic leukemia cell lines using a novel approach called PRECIS, which not only mimicked key mutant characteristics but also revealed new insights into the mutation's role in cancer progression and genome instability.
MiR-155 deficiency and hypoxia results in metabolism switch in the leukemic B-cells.
Cancer Cell Int
July 2024
Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Hypoxia represents one of the key factors that stimulates the growth of leukemic cells in their niche. Leukemic cells in hypoxic conditions are forced to reprogram their original transcriptome, miRNome, and metabolome. How the coupling of microRNAs (miRNAs)/mRNAs helps to maintain or progress the leukemic status is still not fully described.
View Article and Find Full Text PDFPI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia.
Leuk Res
September 2024
Department of Hematology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang 330006, China. Electronic address:
Article Synopsis
- Pirtobrutinib is a non-covalent Bruton's tyrosine kinase (BTK) inhibitor that helps overcome resistance to existing covalent BTK inhibitors in chronic lymphocytic leukemia (CLL), but its resistance mechanisms are not fully understood.
- Researchers created resistant cell models using CRISPR-Cas9 and prolonged drug exposure to evaluate pirtobrutinib resistance, identifying key protein expression changes through advanced analysis techniques.
- The study found that the PI3K/AKT pathway is significantly activated in resistant cells, and using inhibitors targeting this pathway (like CAL101 and MK2206) effectively reduced cell growth and induced cancer cell death, suggesting a potential treatment strategy against resistance.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!